Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Announces Quarterly Earnings Results

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) posted its quarterly earnings data on Thursday. The company reported ($2.23) earnings per share for the quarter, Zacks reports.

Here are the key takeaways from Valion Bio, Inc. Common Stock’s conference call:

• Valion Bio highlighted a major regulatory milestone for Entolimod: NIAID provided the first FDA-precedent gastrointestinal study protocol and will fully fund the BLA-enabling in vivo program, shifting the Animal Rule pathway to a federally supported effort.
• Management said Velocity Bioworks is now operational, with roughly 45 employees on site and a successful 200-fold manufacturing scale-up completed on time and within budget, positioning it as the company’s nearest-term revenue opportunity.
• The company reiterated that Entolimod has broad government interest, including briefings with the U.S. Department of War and a request for information from Ukraine, which management says supports its potential use as a medical countermeasure for acute radiation syndrome.
• Valion Bio outlined a longer-term push into oncology supportive care, with physician-sponsored neutropenia studies expected to begin in the second half of 2026 and six institutional sites already expressing interest.
• First-quarter financials showed higher spending after the company’s biopharma pivot, with operating expenses rising to $5.6 million, net loss widening to $6.2 million, and cash falling to $7.2 million from $12.6 million at year-end, underscoring continued financing needs.

Valion Bio, Inc. Common Stock Stock Performance

Shares of NASDAQ:VBIO traded down $0.05 during midday trading on Friday, reaching $0.88. 368,559 shares of the company traded hands, compared to its average volume of 353,287. The company has a quick ratio of 20.13, a current ratio of 20.13 and a debt-to-equity ratio of 0.38. Valion Bio, Inc. Common Stock has a 12 month low of $0.72 and a 12 month high of $5.60. The firm has a market capitalization of $2.76 million, a price-to-earnings ratio of -0.13 and a beta of 1.86. The firm’s fifty day moving average price is $1.01 and its two-hundred day moving average price is $1.37.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Valion Bio, Inc. Common Stock Company Profile

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.